Log In
BCIQ
Print this Print this
 

INBRX-110

  Manage Alerts
Collapse Summary General Information
Company Inhibrx LLC
DescriptionEngineered mAb designed to activate glucocorticoid-induced TNFR-related protein (GITR) independent of Fc binding
Molecular Target Glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR) (TNFRSF18)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerFive Prime Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$10.0M

$442.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/15/2015

Undisclosed

$10.0M

$442.5M

Get a free BioCentury trial today